$SAGE
Sage Therapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023038739 Filed on August 07, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $2.716M $2.474M
YoY Change 56.18% 64.82%
Cost Of Revenue $900.0K $205.0K
YoY Change 389.13% 2.5%
Gross Profit $1.800M $2.269M
YoY Change 15.76% 74.4%
Gross Profit Margin 66.27% 91.71%
Selling, General & Admin $78.14M $75.57M
YoY Change 27.1% 44.18%
% of Gross Profit 4341.22% 3330.32%
Research & Development $101.9M $97.16M
YoY Change 24.97% 25.7%
% of Gross Profit 5662.17% 4282.11%
Depreciation & Amortization $300.0K $331.0K
YoY Change 7.91% 18.64%
% of Gross Profit 16.67% 14.59%
Operating Expenses $214.6M $172.7M
YoY Change 49.82% 32.96%
Operating Profit -$211.8M -$170.5M
YoY Change 49.74% 32.75%
Interest Expense $10.27M $10.17M
YoY Change 148.95% 383.97%
% of Operating Profit
Other Income/Expense, Net -$55.00K -$41.00K
YoY Change -283.33% -191.11%
Pretax Income -$201.6M -$160.3M
YoY Change 46.81% 26.98%
Income Tax
% Of Pretax Income
Net Earnings -$201.6M -$160.3M
YoY Change 46.83% 26.98%
Net Earnings / Revenue -7423.78% -6480.4%
Basic Earnings Per Share -$3.37 -$2.68
Diluted Earnings Per Share -$3.37 -$2.68
COMMON SHARES
Basic Shares Outstanding 59.88M 59.76M
Diluted Shares Outstanding 59.91M 59.77M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $876.1M $1.003B
YoY Change -37.14% -33.76%
Cash & Equivalents $148.7M $121.4M
Short-Term Investments $727.3M $881.2M
Other Short-Term Assets $34.70M $46.32M
YoY Change -34.55% 11.74%
Inventory
Prepaid Expenses
Receivables $22.51M $15.09M
Other Receivables $0.00 $0.00
Total Short-Term Assets $933.3M $1.064B
YoY Change -36.3% -32.61%
LONG-TERM ASSETS
Property, Plant & Equipment $2.442M $10.04M
YoY Change -13.43% 241.73%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.593M $8.221M
YoY Change 34.3% 67.54%
Total Long-Term Assets $16.39M $18.26M
YoY Change -21.82% -18.81%
TOTAL ASSETS
Total Short-Term Assets $933.3M $1.064B
Total Long-Term Assets $16.39M $18.26M
Total Assets $949.7M $1.082B
YoY Change -36.1% -32.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.14M $9.283M
YoY Change 57.35% 71.59%
Accrued Expenses $114.9M $27.79M
YoY Change 35.17% -63.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $133.0M $96.81M
YoY Change 33.42% 8.48%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $1.105M
YoY Change -100.0% 1005.0%
Total Long-Term Liabilities $0.00 $1.105M
YoY Change -100.0% 1005.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $133.0M $96.81M
Total Long-Term Liabilities $0.00 $1.105M
Total Liabilities $133.0M $97.91M
YoY Change 25.53% 0.79%
SHAREHOLDERS EQUITY
Retained Earnings -$2.537B -$2.335B
YoY Change 33.52% 37.37%
Common Stock $3.358B $3.326B
YoY Change 2.48% 1.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $816.7M $984.4M
YoY Change
Total Liabilities & Shareholders Equity $949.7M $1.082B
YoY Change -36.1% -32.42%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$201.6M -$160.3M
YoY Change 46.83% 26.98%
Depreciation, Depletion And Amortization $300.0K $331.0K
YoY Change 7.91% 18.64%
Cash From Operating Activities -$135.9M -$131.5M
YoY Change 14.33% 23.56%
INVESTING ACTIVITIES
Capital Expenditures $400.0K $112.0K
YoY Change -209.89% -191.8%
Acquisitions
YoY Change
Other Investing Activities $160.7M $45.70M
YoY Change 44.36% -65.99%
Cash From Investing Activities $160.4M $45.59M
YoY Change 44.57% -66.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.800M 847.0K
YoY Change 127.83% 6415.38%
NET CHANGE
Cash From Operating Activities -135.9M -131.5M
Cash From Investing Activities 160.4M 45.59M
Cash From Financing Activities 2.800M 847.0K
Net Change In Cash 27.30M -85.08M
YoY Change -508.44% -405.64%
FREE CASH FLOW
Cash From Operating Activities -$135.9M -$131.5M
Capital Expenditures $400.0K $112.0K
Free Cash Flow -$136.3M -$131.6M
YoY Change 15.02% 23.81%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001597553
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Lessor Operating Lease Option To Extend
LessorOperatingLeaseOptionToExtend
true
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36544
dei Entity Registrant Name
EntityRegistrantName
Sage Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4486580
dei Entity Address Address Line1
EntityAddressAddressLine1
215 First Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02142
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
299-8380
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
SAGE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59883943
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
121416000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
162700000
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
881200000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1109794000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
46321000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
50826000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
1064027000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1336980000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2480000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2898000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1332000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2028170000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1269000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7560000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
10532000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6889000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4770000
CY2023Q2 us-gaap Assets
Assets
1082288000
CY2022Q4 us-gaap Assets
Assets
1356449000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
9283000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
18950000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
79799000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
72666000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7725000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7643000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
96807000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
99259000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1003000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4491000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
102000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
100000
CY2023Q2 us-gaap Liabilities
Liabilities
97912000
CY2022Q4 us-gaap Liabilities
Liabilities
103850000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59799038
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
59512158
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59796005
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59509125
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
6000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
3033
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
3033
CY2023Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
400000
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
400000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3325737000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3291369000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2335323000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.2
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5644000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10206000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
984376000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1252599000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1082288000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1356449000
CY2023Q2 us-gaap Revenues
Revenues
2474000
CY2022Q2 us-gaap Revenues
Revenues
1501000
us-gaap Revenues
Revenues
5768000
us-gaap Revenues
Revenues
3082000
CY2023Q2 sage Cost Of Sales
CostOfSales
205000
CY2022Q2 sage Cost Of Sales
CostOfSales
200000
sage Cost Of Sales
CostOfSales
435000
sage Cost Of Sales
CostOfSales
486000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97161000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
77297000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
189987000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
155315000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
75565000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
52411000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
141273000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
98888000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
172931000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
129908000
us-gaap Operating Expenses
OperatingExpenses
331695000
us-gaap Operating Expenses
OperatingExpenses
254689000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-170457000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-128407000
us-gaap Operating Income Loss
OperatingIncomeLoss
-325927000
us-gaap Operating Income Loss
OperatingIncomeLoss
-251607000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
10173000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2102000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
19003000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3270000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-41000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
45000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-229000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-160325000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-126260000
us-gaap Net Income Loss
NetIncomeLoss
-307153000
us-gaap Net Income Loss
NetIncomeLoss
-248315000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.68
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.68
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.13
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.2
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59769640
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59769640
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59266322
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59266322
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59722147
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59722147
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59148246
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59148246
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-160325000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-126260000
us-gaap Net Income Loss
NetIncomeLoss
-307153000
us-gaap Net Income Loss
NetIncomeLoss
-248315000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-556000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2671000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
4562000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-11212000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-556000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2671000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
4562000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-11212000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-160881000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-128931000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-302591000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-259527000
us-gaap Profit Loss
ProfitLoss
-307153000
us-gaap Profit Loss
ProfitLoss
-248315000
us-gaap Share Based Compensation
ShareBasedCompensation
31731000
us-gaap Share Based Compensation
ShareBasedCompensation
33189000
sage Premium On Marketable Securities
PremiumOnMarketableSecurities
71000
sage Premium On Marketable Securities
PremiumOnMarketableSecurities
1454000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
7570000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-6114000
us-gaap Depreciation
Depreciation
654000
us-gaap Depreciation
Depreciation
554000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4505000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1614000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
1430000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
5216000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
2119000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
656000
sage Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-2972000
sage Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-2730000
sage Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
82000
sage Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
95000
sage Increase Decrease In Operating Lease Liabilities Non Current
IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent
-3488000
sage Increase Decrease In Operating Lease Liabilities Non Current
IncreaseDecreaseInOperatingLeaseLiabilitiesNonCurrent
-3164000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-9566000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5225000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
6253000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
8723000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-285200000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-214239000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
630452000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
556100000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
389655000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
431105000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
337000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
291000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
240460000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
124704000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
4156000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1836000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
637000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
24000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3519000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1812000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-41221000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-87723000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
163969000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
295502000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
122748000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
207779000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
36000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
256000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1729031000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
646000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1153000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
18268000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-8541000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-122055000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1618502000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
37000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14652000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-2671000
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-24000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-126260000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1504236000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1252599000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
438000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2863000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19568000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
5118000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-629000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-146828000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1133129000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
855000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11281000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-556000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-8000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-160325000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
984376000
CY2020 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
606100000
us-gaap Proceeds From Collaborators
ProceedsFromCollaborators
1000000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period</span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
120180000
CY2023Q2 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
881200000
CY2023Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1001380000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
161185000
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
1109794000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1270979000
CY2023Q2 sage Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount
FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
0
CY2022Q2 sage Fair Value Assets Transfers Among Level1 Level2 And Level3 Amount
FairValueAssetsTransfersAmongLevel1Level2AndLevel3Amount
0
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
886844000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5650000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
881200000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1120000000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
44000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
10250000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1109794000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
656838000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
3410000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
154177000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
2240000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
811015000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
5650000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
513738000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
4795000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
399783000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
5455000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
913521000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
10250000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2023Q2 sage Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
45322000
CY2022Q4 sage Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
32565000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
19194000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
29372000
CY2023Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
14413000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
10172000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
870000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
557000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
79799000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
72666000
CY2023Q2 us-gaap Lessor Operating Lease Renewal Term
LessorOperatingLeaseRenewalTerm
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
sage Share Based Compensation Arrangement By Share Based Payment Award Award Cliff Vesting Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod
P1Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10907261
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
7968438
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
1415481
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
48.73
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
1192938
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
42.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
153067
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
65.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
50016
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
46.64
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
2405336
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
44.86
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11693000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14636000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31731000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
33189000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11693000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14636000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31731000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
33189000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
30.41
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
26.32
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-160325000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-126260000
us-gaap Net Income Loss
NetIncomeLoss
-307153000
us-gaap Net Income Loss
NetIncomeLoss
-248315000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59769640
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59266322
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59722147
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
59148246
CY2023Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
CY2022Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59769640
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59266322
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59722147
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
59148246
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.68
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.68
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.13
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.14
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.2
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.2
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8385284
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7276589
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8385284
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7276589
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-23-038739-index-headers.html Edgar Link pending
0000950170-23-038739-index.html Edgar Link pending
0000950170-23-038739.txt Edgar Link pending
0000950170-23-038739-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img93201763_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sage-20230630.htm Edgar Link pending
sage-20230630.xsd Edgar Link pending
sage-ex10_1.htm Edgar Link pending
sage-ex10_2.htm Edgar Link pending
sage-ex10_3.htm Edgar Link pending
sage-ex10_4.htm Edgar Link pending
sage-ex10_5.htm Edgar Link pending
sage-ex10_6.htm Edgar Link pending
sage-ex31_1.htm Edgar Link pending
sage-ex31_2.htm Edgar Link pending
sage-ex32_1.htm Edgar Link pending
Show.js Edgar Link pending
sage-20230630_def.xml Edgar Link unprocessable
sage-20230630_pre.xml Edgar Link unprocessable
sage-20230630_htm.xml Edgar Link completed
sage-20230630_lab.xml Edgar Link unprocessable
sage-20230630_cal.xml Edgar Link unprocessable